VBI Vaccines Announces Pricing Of $18M Public Offering And $3M Concurrent Registered Direct Offering
Portfolio Pulse from Happy Mohamed
VBI Vaccines Inc. has announced the pricing of its underwritten public offering and concurrent registered direct offering, which are expected to generate approximately $21 million in gross proceeds. The funds will be used for the commercialization of PreHevbrio in the US, Europe, and Canada, manufacturing of PreHevbrio and clinical materials for its pipeline programs, and ongoing activities related to its development stage candidates, including VBI-1901 and VBI-2901.
July 06, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines' public and direct offerings are expected to generate $21 million, which will be used for commercialization and development activities. This could potentially boost the company's financial position and future prospects.
The news of the offerings and the intended use of the proceeds for commercialization and development activities is directly related to VBI Vaccines and could potentially have a positive impact on the company's stock price in the short term. The funds will be used to advance the company's pipeline programs and commercialize its product, which could enhance its financial position and future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100